Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SDX-105 (Bendamustine) + Rituximab in Relapsed Indolent or Mantle Cell NHL
NCT00076349Phase 2Completed
- Sponsor
- Cephalon, Inc.
- Start
- Apr 2004
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of bendamustine in Indolent Non-Hodgkin Lymphoma (INHL), mantle cell lymphoma (MCL), sponsored by Cephalon, Inc.. Started Apr 2004; status: completed.
02
Drugs
bendamustine
03
Conditions
Indolent Non-Hodgkin Lymphoma (INHL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00076349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076349.